Parkinson's Institute, Berg launch 3rd phase of biomarker study

02/20/2014 | GenomeWeb Daily News (free registration)

The Parkinson's Institute and Clinical Center and biopharmaceutical company Berg will conduct a study to validate previously identified biomarkers for Parkinson's disease. This phase of the ongoing collaboration to identify biomarkers that could lead to better research, diagnosis and treatment of Parkinson's disease involves analysis of Parkinson's patients' urine, blood and other tissue samples to identify differences between healthy and diseased tissues.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ